Table 1 Baseline clinical characteristics

From: Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results

Variable

 

Total

  

N

%

Age at inclusion (years)

Median (range)

54 (45–60)

 

Gender

Male

32

52

Female

29

48

ECOG PS

0

22

36

1

39

64

Sarcomas histology

Leiomyosarcoma

17

28

Liposarcoma

7

12

Solitary fibrous tumor

7

12

Others subtypes

30

49

Prior treatmentsa

Surgery

60

98

Radiotherapy

44

72

Chemotherapy/TT

60

98

Median N lines (range)

5 (0–9)

 

Tumor TLS

Yes

0

0

No

35

57

NA

26

43

Atezolizumabb

Median N cycles (range)

10 (0–50)

 

SBRT (Gy)

Median dose (range)

41 (30–45)

 

Irradiated sites (n = 72)

Lung

36

50

Bone

9

13

Others

27

37

  1. TT targeted therapies, TLS tertiary lymphoid structures, NA not available
  2. aPatients had several treatments so the sum of percentages is above 100
  3. bOne did not receive atezolizumab
Back to article page